

## **EXHIBIT 2**

IN THE UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS

In re: NEURONTIN  
MARKETING, SALES  
PRACTICES and PRODUCTS  
LIABILITY LITIGATION

MDL Docket No. 1629  
Master File No.  
04-10981  
Judge Patti B. Saris  
Magistrate Judge  
Leo T. Sorokin

RUTH SMITH,

Plaintiff, C. A. No. 05-11515  
v.

PFIZER, INC., et al.,

Defendants.

Videotaped Deposition of:

EDWARD MACKEY, M.D.

Wednesday, May 23, 2007

1  
2       **STIPULATIONS**  
3       It is stipulated and agreed, by  
4 and between the parties through their  
5 respective counsel, that the videotaped  
6 deposition of:

7       EDWARD MACKEY, M.D., may be  
8 taken before Fred W. Jeske, court reporter and  
9 Tennessee Notary Public, at the offices of  
10 Miller & Martin, 1200 US Bank Tower, 150 Fourth  
11 Avenue, North, Nashville, Tennessee, on  
12 Wednesday, May 23, 2007, commencing at  
13 approximately 8:40 a.m.

14      It is further stipulated and  
15 agreed that the signature to and reading of the  
16 deposition by the witness is waived, the  
17 deposition to have the same force and effect as  
18 if full compliance had been had with all laws  
19 and rules of Court relating to the taking of  
20 depositions.

21  
22  
23  
24  
25

1      APPEARANCES:  
2      For the Plaintiff:  
3       ANDREW G. FINKELSTEIN  
4       KEITH ALTMAN  
5       Finkelstein & Partners  
6       436 Robinson Avenue  
7       Newburgh, New York 12550  
8       (800) 634-1212  
9       afinkelstein@lawampm.com  
10      -and-  
11       W. MARK LANIER  
12       ROBERT LEONE  
13       DARA HEGAR  
14       PATRICK O'HARA  
15       The Lanier Law Firm  
16       6810 FM 1960 West  
17       Houston, Texas 77069  
18       Post Office Box 691448  
19       Houston, Texas 77269-1448  
20       (713) 659-5200  
21       wmj@lanierlawfirm.com

22      For the Defendant Pfizer:  
23       KENNETH J. FERGUSON  
24       CEDRIC E. EVANS  
25       Clark, Thomas & Winters  
1       300 West 6th Street, 15th Floor  
2       Austin, Texas 78701  
3       P.O. Box 1148  
4       Austin, Texas 78767  
5       (512) 472-8800  
6       ceef@ctw.com  
7      For the witness:  
8       NOEL F. STAHL  
9       Miller & Martin  
10      1200 one Nashville Place  
11      150 Fourth Avenue North  
12      Nashville, Tennessee 37219  
13      (615) 744-8503  
14      nstahl@millermartin.com

15      Also present:  
16      Jonathan Wilkerson, law clerk  
17      Sheldon Singh, videographer  
18      -oo-

1  
2      It is further stipulated and  
3 agreed that it shall not be necessary for any  
4 objections to be made by counsel to any  
5 questions, except as to form or leading  
6 questions, and that counsel for the parties may  
7 make objections and assign grounds at the time  
8 of the trial, or at the time said deposition is  
9 offered in evidence, or prior thereto.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

	TABLE OF CONTENTS	Page
	EDWARD MACKEY, M.D.	
3	Direct By Mr. Lanier	7
4	Cross By Mr. Ferguson	44
5	Re-Direct By Mr. Lanier	93
6	Re-Cross By Mr. Ferguson	107
7	EXHIBITS	
8	Exhibit Description	Page
9	Exhibit 1 Curriculum vitae	8
10	Exhibit 2 Medical records	8
11	Exhibit 3 Pfizer records	15
12	Exhibit 4 Neurontin product label	18
13	Exhibit 5 Information	21
14	Exhibit 6 FDA Division of	35
15	Neuropharmacological Drug	
16	Products Combined	
17	Medical-Statistical Review	
18	10/13/93	
19	Exhibit 7 Affidavit of David Franklin, 38	
20	Ph.D.	
21	REPORTER'S CERTIFICATE	
22	-oo-	112
23		
24		
25		

1           VIDEOGRAPHER: My name is  
 2 Sheldon Singh of Nationwide Video  
 3 Productions, Inc., located in Roseland, New  
 4 Jersey.

5           Today's date is Wednesday, May  
 6 23rd, 2007, and the time on the monitor is  
 7 8:40 a.m. This deposition is being held in  
 8 the office of Miller and Martin, located at  
 9 150 Fourth Avenue, North, Nashville,  
 10 Tennessee, 37219.

11          The caption of this case is  
 12 Neurontin Marketing, Sales Practices and  
 13 Products Liability Litigation, Ruth Smith  
 14 v. Pfizer, Inc., et al.

15          The case number is 05-11515, in  
 16 the United States District Court, District  
 17 of Massachusetts.

18          The name of the witness is  
 19 Dr. Edward S. Mackey.

20          At this time the attorneys will  
 21 identify themselves and the parties they  
 22 represent after which our court reporter,  
 23 Mr. Fred Jeske, of Vowell & Jennings, will  
 24 swear in the witness so we can proceed.

25          MR. LANIER: My name is Mark

1           middle of the day to come down to the  
 2 courthouse to testify. But we do recognize you  
 3 taking time today, and we appreciate it.

4           I have a copy of what's your  
 5 curriculum vitae, kind of a resume type thing.  
 6 I'm marking it as Exhibit 1.  
 7 (Exhibit 1 marked.)

8          Q.    Would you confirm for the jury that  
 9 that's who you are.

10         A.    Yes.

11         Q.    Thank you. And then we have brought --  
 12 you have brought today a copy of your medical  
 13 records on Mr. Smith. We're going to mark that  
 14 as Exhibit 2 and we'll attach that as well.

15 (Exhibit 2 marked.)

16         Q.    Is that a full and complete copy of  
 17 those records, sir, to the best of your  
 18 knowledge?

19         A.    I, I believe so.

20         Q.    Okay. I assume you didn't make the  
 21 copies yourself personally but you asked for a  
 22 copy to be made?

23         A.    That is correct.

24         Q.    All right. Thank you. Please feel  
 25 free to refer to that as you need to throughout

1          Lanier. I'm here with a number of folks  
 2 representing the Smith family. I've got  
 3 from my office Bob Leone, Andrew  
 4 Finkelstein from his office is here, along  
 5 with Keith.

6          We've got Dara Hegar. We've got  
 7 Patrick O'Hara, and we've got -- and we  
 8 have got Jonathan Wilkerson here from our  
 9 office.

10         MR. FERGUSON: Ken Ferguson,  
 11 Clark, Thomas and Winters, in Austin, Texas  
 12 for Pfizer, Parke-Davis and Warner-Lambert  
 13 along with Cedric Evans from the same firm.

14         MR. STAHL: I'm Noel Stahl. I'm  
 15 here with Dr. Ed Mackey.

16         EDWARD MACKEY, M.D.,  
 17 having been duly sworn, testified as follows:

18         DIRECT EXAMINATION

19         BY MR. LANIER:

20         Q.    Dr. Mackey, thank you for taking time  
 21 to be with us today. We appreciate it.

22         We have an opportunity to take  
 23 your deposition by videotape so that a jury's  
 24 able to listen and watch your testimony, and  
 25 you don't have to stop your practice in the

1          the deposition, and we'll try not to take too  
 2 much of your time today.

3           First a little bit about you.

4          What kind of doctor are you?

5         A.    I'm an orthopedic surgeon.

6         Q.    In everyday language what's an  
 7 orthopedic surgeon?

8         A.    It's a doctor specializing in the care  
 9 of bones and muscles of the body.

10        Q.    If I have got a problem with my back,  
 11 are you the kind of doctor I'd go see?

12        A.    Yes.

13        Q.    Okay. Did you have a chance to look at  
 14 and take care of some Richard Smith?

15        A.    Yes.

16        Q.    And that's the gentleman whose chart  
 17 you have in front of you; right?

18        A.    Yes.

19        Q.    What, if you could tell the jury, is  
 20 the time period when you gave your care for  
 21 Mr. Smith?

22        A.    I first saw Mr. Smith February 12th,  
 23 2004.

24        Q.    And so that we get the other bookend in  
 25 place, when was your last time to see

1 A. Yes, I do.  
 2 Q. Sir, Neurontin is the drug that we're  
 3 discussing; right?  
 4 A. Yes.  
 5 Q. Now you're not a pharmacist yourself?  
 6 A. No.  
 7 Q. And I assume that you've got a full  
 8 slate of patients, so you spend most of your  
 9 time trying to treat people and help them get  
 10 well and doing surgery?  
 11 A. Yes.  
 12 Q. You're not a drug researcher who is out  
 13 there doing independent research to figure out  
 14 what drugs do and how they do it, are you?  
 15 A. No.  
 16 MR. FERGUSON: Object to form.  
 17 A. No.  
 18 Q. (By Mr. Lanier) Have you ever had a  
 19 chance to look at the actual label for  
 20 Neurontin, yourself? And let me, let me  
 21 preface that by giving you a copy. So -- I'm  
 22 sure you've glanced at it or something, but I  
 23 want to ask you some questions about it. So  
 24 we'll mark it as Exhibit 4.  
 25 A. Okay.

1 (Exhibit 4 marked.)  
 2 Q. And I will represent to you this is a  
 3 copy of the label at the time that you had  
 4 prescribed it for Mr. Smith. And ask you to  
 5 take a moment and just sort of look at it. I'm  
 6 going to specifically direct your attention to  
 7 the indications, on page 10 of this copy.  
 8 A. Yes.  
 9 Q. Do you have that in front of you?  
 10 A. I do.  
 11 Q. Now there are two indications that  
 12 Pfizer has given for their drug, one is for  
 13 postherpetic neuralgia, which I understand  
 14 means the management of shingles pain; is that  
 15 right?  
 16 A. Yes.  
 17 Q. Obviously you weren't prescribing this  
 18 for shingles, were you?  
 19 A. No.  
 20 Q. The second is for epilepsy, partial  
 21 seizures. Do you see that as well?  
 22 A. I do.  
 23 Q. And I assume you were not prescribing  
 24 this for epileptic reasons either.  
 25 A. No.

1 Q. Sir, those are the only two indications  
 2 that the FDA allowed Pfizer to put into their  
 3 label. Do you see that?  
 4 A. Yes.  
 5 Q. I want to ask you some questions about  
 6 what your knowledge was about what Pfizer was  
 7 doing off label as far as their drug, so I'm  
 8 going to ask you a series of questions here,  
 9 and I will try and provide you the information.  
 10 I want to see if this is information that you  
 11 had even found out yourself, okay?  
 12 MR. FERGUSON: Object to form.  
 13 Q. (By Mr. Lanier) Did you know that  
 14 over 90, 90 percent of Pfizer's sales for  
 15 Neurontin were for off-label uses?  
 16 MR. FERGUSON: Object to form.  
 17 A. I knew it at some point. I don't know  
 18 when I knew that.  
 19 Q. (By Mr. Lanier) And by off-label uses,  
 20 you understand we're talking about  
 21 prescriptions being written to use the drug for  
 22 reasons that the FDA never approved in the  
 23 label; right?  
 24 A. Yes.  
 25 Q. Did you know that on the very day of

1 Mr. Smith's death that Pfizer filed with a  
 2 court a plea agreement basically setting  
 3 forward the fact that they had not been  
 4 following the law on the way they were  
 5 marketing their drug?  
 6 MR. FERGUSON: Object to form.  
 7 Q. (By Mr. Lanier) Did you know about  
 8 that?  
 9 A. Um, yes. That was widely reported in  
 10 the news.  
 11 Q. Okay. Didn't know about it beforehand,  
 12 that it had been going on, but once it happened  
 13 you found out about it, is that fair to say?  
 14 MR. FERGUSON: Object to form.  
 15 A. I don't recall exactly what I knew at  
 16 what point, but I certainly knew after the  
 17 lawsuit was discussed or settled.  
 18 Q. Okay.  
 19 A. The issues.  
 20 (Exhibit 5 marked.)  
 21 Q. (By Mr. Lanier) If you'll look at  
 22 Exhibit 5. It's a legal pleading, we call it  
 23 an information, but it basically sets up the  
 24 ultimate plea agreement with the court. And  
 25 you can go to the very last page of it, page

1 abstracts and case reports in promoting  
 2 Parke-Davis's prescription drugs, including  
 3 Neurontin, for a variety of medically  
 4 unacceptable uses. Do you see that as well?  
 5 A. Yes.  
 6 Q. Sir, as a doctor, is it important to  
 7 you that drug companies put patient safety  
 8 first?  
 9 A. Yes.  
 10 Q. Is it important to you that drug  
 11 companies follow FDA instructions and rules and  
 12 guidelines --  
 13 MR. FERGUSON: Object to form.  
 14 Q. -- about what they're telling you and  
 15 what they're not?  
 16 A. Yes.  
 17 Q. (By Mr. Lanier) Now if you had been  
 18 told either in the labeling information or  
 19 through sales reps or, Dr. Mackey, through your  
 20 partners, if you had been told that Neurontin  
 21 was a drug with some of the problems we've  
 22 talked about so far today, would it have  
 23 changed the way you treated Mr. Smith?  
 24 MR. FERGUSON: Object to form.  
 25 A. Possibly. Probably.

1 Q. All right. How did you find out about  
 2 his death?  
 3 A. His wife called our office and spoke  
 4 with our telephone answering operator and then  
 5 spoke with my nurse.  
 6 Q. Okay. Did you by any chance file a  
 7 MedWatch report with the FDA after this, do you  
 8 know?  
 9 A. I don't know. I don't think I've  
 10 ever -- I don't know to do that or --  
 11 Q. Yeah. I didn't think so, but I didn't  
 12 see one, and I just wasn't sure.  
 13 MR. LANIER: I'm going to, I've  
 14 used 45 of my minutes. I'm going to save  
 15 my other 45. I'm going to pass the witness  
 16 and see if he can really do it in 44.  
 17 MR. FERGUSON: Doctor, are you  
 18 doing okay? Do you need a break or  
 19 anything?  
 20 THE WITNESS: I'm okay.  
 21 CROSS-EXAMINATION  
 22 BY MR. FERGUSON:  
 23 Q. Dr. Mackey, we met briefly before the  
 24 deposition. My name is Ken Ferguson. I  
 25 represent Pfizer in this matter. Do you

1 Q. (By Mr. Lanier) Probably. And by  
 2 probably, would it have meant you would have  
 3 either tried another drug first, or would you  
 4 have at least put out some warnings and some  
 5 safeties and precautions and told them what to  
 6 be observant about?  
 7 MR. FERGUSON: Object to form.  
 8 A. Certainly I would have done the  
 9 latter.  
 10 Q. Okay.  
 11 A. And I don't know about the former.  
 12 Q. (By Mr. Lanier) All right. Now if  
 13 someone's at risk of -- I don't know that you  
 14 see often someone that you consider a suicide  
 15 risk in your practice, but if you see someone  
 16 that presents that you think is a serious  
 17 candidate for suicide, I would assume you would  
 18 do something about that. There is some  
 19 protocol.  
 20 A. Yes.  
 21 Q. Okay. Mr. Smith, when he presented to  
 22 you, I've read through your chart, there's  
 23 nothing about him that made you think he was a  
 24 suicide risk when he presented, was there?  
 25 A. No.

1 understand that?  
 2 A. Yes.  
 3 Q. Doctor, you graduated from Dartmouth  
 4 undergrad; correct?  
 5 A. Yes.  
 6 Q. And you went to Vanderbilt University  
 7 Medical School right here?  
 8 A. Yes.  
 9 Q. You're board certified in orthopedic  
 10 surgery?  
 11 A. I am.  
 12 Q. You're board certified in spine surgery  
 13 also; correct?  
 14 A. Yes.  
 15 Q. Generally, do you make your own  
 16 decisions about how you treat your patients?  
 17 A. Yes.  
 18 Q. Nobody's going to tell you how to treat  
 19 your patients, are they?  
 20 A. No.  
 21 Q. I want to follow up a bit on some of  
 22 the care and treatment you actually performed  
 23 on Mr. Smith, if I could, okay?  
 24 Mr. Lanier spoke about that  
 25 briefly. Let me ask you some questions.

1 you that I recall for sure, --  
 2 Q. Um-hum.  
 3 A. -- that I had samples in my closet for  
 4 distribution to patients.  
 5 Q. Okay. And did you distribute those  
 6 samples?  
 7 A. I did.  
 8 Q. And those samples are always  
 9 accompanied by their product labeling, aren't  
 10 they?  
 11 A. I believe so. I think each box comes  
 12 with one.  
 13 Q. We talked about the fact that Lortab or  
 14 narcotic pain relievers have potential for  
 15 addictive behavior. To your knowledge, does  
 16 Neurontin have potential for addictive  
 17 behavior?  
 18 A. I'm not aware of it.  
 19 Q. Do some medications have the potential  
 20 to damage the liver, because they're  
 21 metabolized through the liver?  
 22 A. Yes.  
 23 Q. Do you know if Neurontin fits that  
 24 category or not?  
 25 A. I believe it goes through the kidney.

1 A. A long time ago, probably.  
 2 Q. There was a lot of discussion on the  
 3 prior examination regarding off-label use  
 4 versus on-label use. Do you understand that  
 5 distinction?  
 6 A. Quite well.  
 7 Q. And really off-label use can, can  
 8 include indications that aren't labeled;  
 9 correct?  
 10 A. Right.  
 11 Q. Off-label use can also include for --  
 12 in dosages not labeled; correct?  
 13 A. I didn't realize that as well, but yes,  
 14 that makes sense.  
 15 Q. Okay. Is it uncommon or common for  
 16 doctors to prescribe medications for unlabeled  
 17 indications?  
 18 A. I, I imagine it's relatively common. I  
 19 don't know to what extent it is.  
 20 Q. Okay. Is Neurontin the only medication  
 21 you have ever prescribed off-label?  
 22 A. I don't know.  
 23 Q. Do you know whether or not the FDA  
 24 recognizes and even approves the prescription  
 25 of drugs off-label?

1 Q. And you noted that you had had success  
 2 with Neurontin with other patients prior to  
 3 Mr. Smith?  
 4 A. Yes.  
 5 Q. And you have had success with Neurontin  
 6 since prescribing for Mr. Smith.  
 7 A. Yes.  
 8 Q. Was the fact that you had had success  
 9 in treating other patients with Neurontin a  
 10 factor in making the decision to prescribe for  
 11 Mr. Smith?  
 12 A. Among others, yes.  
 13 Q. Other than the discussions that you  
 14 think may have taken place, probably took place  
 15 with sales representatives, did you receive any  
 16 other information from any source of Pfizer,  
 17 Warner-Lambert, Parke-Davis regarding the use  
 18 of Neurontin, that you recall?  
 19 A. Not that I recall.  
 20 Q. And I think Mr. Lanier asked you this,  
 21 but I can't recall exactly what your answer  
 22 was. With regard to the PDR information, the  
 23 labeling information regarding Neurontin, had  
 24 you reviewed that at some point prior to  
 25 prescribing for Mr. Smith?

1 A. Um, again, I don't know.  
 2 Q. Okay. Does the FDA try to --  
 3 MR. STAHL: Four minutes.  
 4 MR. FERGUSON: Thank you.  
 5 Q. (By Mr. Ferguson) Does the FDA ever,  
 6 to your knowledge, try to tell doctors how to  
 7 practice medicine?  
 8 A. No.  
 9 Q. During the period of time that you --  
 10 you said you may have reviewed the Neurontin  
 11 label sometime prior to having prescribed for  
 12 Mr. Smith. Do you re-review labeling on an  
 13 annual basis or on any kind of a regular basis  
 14 or not, on medications that you prescribe  
 15 regularly?  
 16 A. Ah, not typically.  
 17 I guess, you know, those type of  
 18 updates or changes I sort of rely on  
 19 information coming to me.  
 20 Q. Do you know one way or the other  
 21 whether in the label in, say, 2003-2004 time  
 22 frame, there was any information in the label  
 23 regarding suicidal behavior or suicidal  
 24 gesture?  
 25 A. Do I -- did I know that in 2004?

1 Q. Yes, sir.  
 2 A. No, I did not.  
 3 Q. As you sit here today, do you know  
 4 whether or not there was --  
 5 A. Yeah.  
 6 Q. -- such information in the label back  
 7 in 2003-2004?  
 8 A. Yes. Among many other issues.  
 9 Q. As -- and if I'm getting out your area  
 10 you just let me know. But as someone who  
 11 treats chronic pain patients, and I realize you  
 12 treat them for certain, in certain situations.  
 13 And you would have your colleagues in your  
 14 office treat other kinds of chronic pain. But  
 15 you do treat chronic pain patients; correct?  
 16 A. Um, if they're -- if I can manage them  
 17 surgically, I will.  
 18 Q. Um-hum.  
 19 A. If I cannot, I sent them out to someone  
 20 who does that.  
 21 Q. Do you know one way or the other  
 22 whether individuals who have long-term chronic  
 23 pain are more likely or less likely to commit  
 24 suicide than the normal population?  
 25 A. You're right, I think you're outside my

1 in the 2003-2004 time frame there was some  
 2 information about suicidal conduct, suicidal  
 3 gesture in the, the Neurontin labeling;  
 4 correct?  
 5 A. It's in the PDR, 2004.  
 6 Q. Right. When did you become aware of  
 7 that?  
 8 A. Preparing for this deposition.  
 9 Q. And the fact of that was in there,  
 10 that's not keeping you from prescribing  
 11 Neurontin to anybody, is it?  
 12 A. I wouldn't say to anybody, but it has  
 13 not -- I still will prescribe it.  
 14 Q. Okay. Are you aware of any, any  
 15 labeling changes that took place with regard to  
 16 Neurontin in the 2004-2005 time frame?  
 17 A. I'm not aware of any.  
 18 Q. Mr. Lanier talked to you about  
 19 Exhibit 6, which is, he represented, as an FDA  
 20 document. Do you recall that discussion?  
 21 A. Yes.  
 22 Q. And he showed you I think one page of  
 23 this. This is about a hundred and -- I don't  
 24 know how many page document. Hundred and  
 25 something page document; correct?

1 area of expertise.  
 2 Q. Okay. Fair enough.  
 3 VIDEOGRAPHER: One minute  
 4 remaining.  
 5 MR. FERGUSON: Why don't we go  
 6 ahead and break real quick since we have  
 7 one minute left, and then I'll try to  
 8 finish up here quickly.  
 9 VIDEOGRAPHER: We're going off  
 10 the record. This marks the end of tape  
 11 number 1. The time on the monitor is  
 12 10:02. Tape number 1. Going off the  
 13 record.  
 14 (Recess from 10:02 to 10:17 a.m.)  
 15 VIDEOGRAPHER: Stand by.  
 16 We're coming back on the record.  
 17 This marks the beginning of tape number 2.  
 18 Time on the monitor is 10:17.  
 19 You may proceed, counselor.  
 20 Q. (By Mr. Ferguson) Okay, Doctor, we  
 21 have taken a break. Are you ready to  
 22 proceed?  
 23 A. I am.  
 24 Q. We were talking a little bit earlier  
 25 about the fact that you are aware now that back

1 A. Yes.  
 2 Q. Okay. You haven't reviewed the whole  
 3 document?  
 4 A. No.  
 5 Q. Okay. And if as you -- 119 pages. If  
 6 as he represented to you this is an FDA  
 7 document, the FDA had whatever information was  
 8 in here when it approved the Neurontin  
 9 labeling; correct?  
 10 A. I would assume so.  
 11 Q. And I think he asked you if you would  
 12 like to have known the information that he  
 13 pointed out in there; correct? Do you recall  
 14 that?  
 15 A. Yeah, any, any relevant information I  
 16 would like --  
 17 Q. Sure.  
 18 A. -- to have available.  
 19 Q. And this referred, this document,  
 20 Exhibit 6, referred to a suicide attempt that  
 21 may have occurred, or suicide in connection  
 22 with someone who was on Neurontin; correct?  
 23 MR. LANIER: Page 117.  
 24 Q. (By Mr. Ferguson) Page 117.  
 25 A. Okay. I'm sorry, what was your

1 Q. Including potential suicides?  
 2 A. Statistically I'm sure, yes.  
 3 Q. Okay. And the population taking  
 4 Neurontin are people with pain?  
 5 A. Yes.  
 6 Q. To your knowledge, epilepsy; correct?  
 7 A. Yes.  
 8 Q. And do both of those conditions, if you  
 9 know, have increased possibility of suicide?  
 10 A. I do not know.  
 11 Q. Okay. If 12 million people took  
 12 Neurontin worldwide, would, would it give you  
 13 concern one way or the other if there were 35  
 14 suicides reported in connection with that?  
 15 MR. LANIER: What do you mean by  
 16 "report"?"  
 17 MR. FERGUSON: Has adverse  
 18 events.  
 19 MR. LANIER: Are you talking  
 20 about like filing those MedWatch things?  
 21 MR. FERGUSON: I'm talking about  
 22 adverse events reported to the company.  
 23 Like to say anything else?  
 24 MR. LANIER: Well, he hadn't  
 25 even filed a MedWatch. These doctors don't

1 Q. With regard to this gentleman named  
 2 David Franklin, who Mr. Lanier talked to you  
 3 about, you never met Mr. Franklin, did you, or  
 4 Dr. Franklin?  
 5 A. No. Again, not that I'm aware of.  
 6 Q. And he read, read you some what  
 7 purported to be a quote from a guy named Phil  
 8 Magistro, a phone conversation or something.  
 9 You don't know Mr. Phil Magistro, do you?  
 10 A. No.  
 11 Q. Given the information you have today  
 12 going, going into today, as we discussed,  
 13 you're still prescribing Neurontin for some  
 14 patients?  
 15 A. Selectively, yes.  
 16 Q. And my understanding from your  
 17 testimony, Mr. Lanier is, based on what you  
 18 know today, you don't know one way or the other  
 19 whether you would still prescribe for  
 20 Mr. Smith, is that accurate?  
 21 A. If Mr. Smith came into my office today,  
 22 I would not prescribe him Neurontin as -- he  
 23 would have gotten Lyrica.  
 24 Q. Okay. Lyrica wasn't available in 2004,  
 25 was it?

1 do that. You can't even look at those.  
 2 But I'll -- I shouldn't be saying that.  
 3 I'm saving that for redirect. Go ahead.  
 4 MR. FERGUSON: Thank you.  
 5 Q. (By Mr. Ferguson) Doctor, if 12  
 6 million people took it, would it surprise you  
 7 if there were 35 suicides reported in  
 8 connection with those 12 million?  
 9 A. Probably not. But I would want to know  
 10 the details surrounding that.  
 11 Q. Sure. Sure. Fair enough. If 12  
 12 million people take something and a certain  
 13 number of things are going to occur by, by  
 14 chance alone; correct?  
 15 A. Right. And but you also have to weigh  
 16 the relative complications --  
 17 Q. Sure.  
 18 A. -- to the frequency.  
 19 Q. And I take it you're not an expert in  
 20 epidemiology, fair enough?  
 21 A. Fair enough.  
 22 Q. Okay. And with regard to the  
 23 epidemiology of suicide, you're specifically  
 24 not an expert; correct?  
 25 A. No.

1 A. No. Not that I'm aware of. Not that I  
 2 recall.  
 3 Q. Okay.  
 4 MR. FERGUSON: I think that's  
 5 all I have for now, Doctor. Thank you very  
 6 much.  
 7 THE WITNESS: All right.  
 8 MR. LANIER: You know, he did  
 9 better on time than I thought he was going  
 10 to. I got to give it to you.  
 11 MR. FERGUSON: Appreciate it.  
 12 REDIRECT EXAMINATION  
 13 BY MR. LANIER:  
 14 Q. I want to go back through some  
 15 questions that were just asked of you and make  
 16 sure I understand some of the answers, okay?  
 17 You were first asked, is it true  
 18 that you decide how to treat patients and  
 19 nobody tells you how to do it. Do you remember  
 20 those questions?  
 21 A. Yes, I do remember that question.  
 22 Q. Let me understand how you do this,  
 23 please. You certainly are the doctor, and you  
 24 make your recommendations, is that fair to  
 25 say?